Ockenhouse, C F <br/><br/>
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.  [electronic resource] 

 -  The Journal of infectious diseases  Jun 1998 
 - 1664-73 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>0022-1899 
<br/><br/><label>Standard No.: </label>10.1086/515331  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Amino Acid Sequence<br/>Antibodies, Protozoan--immunology<br/>Antigens, Protozoan--adverse effects<br/>Consumer Product Safety<br/>Female<br/>Genetic Vectors<br/>Humans<br/>Malaria Vaccines--adverse effects<br/>Male<br/>Middle Aged<br/>Molecular Sequence Data<br/>T-Lymphocytes, Cytotoxic--immunology<br/>Vaccines, Attenuated--adverse effects<br/>Vaccines, Synthetic--adverse effects<br/>Vaccinia virus<br/>Viral Proteins--adverse effects<br/>Viral Vaccines--adverse effects